RE:Enterprise Value to Sales for Pharmaceuticals ( Drugs )
I am a bit more critical of the company for one reason only...look at the 3 year price chart of medicure. The only person who might like this chart is a downhill skier. Now, I am grateful for the tender offer, which I took full advantage of....so in a sense, the CEO is cognizant of the abysmal share price. I just wish the co. had more going for it. The primary cash cow, aggrastat, has it's patent expiring in 2023. ReDs sales trajectory is poor, a decline from $100k to substantially below that means that willingness to adopt this tech. is not there--meaning there is already a viable alternative. And honestly, who needs another statin with so many cheap alternatives already on the market. I'm negative on the company for a reason.